Regulation
FDA committee endorses Johnson & Johnson’s multiple myeloma therapy
The ODAC recommendation follows a review of data from the Phase III CARTITUDE-4 study.
The ODAC recommendation follows a review of data from the Phase III CARTITUDE-4 study.